Circular Dichroism (CD) spectroscopy works by passing circularly polarized light through a sample and measuring how differently the molecule absorbs left- and right-handed light. Because folded proteins, structured peptides, nucleic acids, and chiral small molecules interact with this light in characteristic ways, CD spectra can reveal molecular shape, folding state, conformational stability, and optical activity without labeling the sample. For pharmaceutical researchers, drug development scientists, formulation teams, and CRO partners, CD data can clarify whether a protein is folded as intended, whether a peptide retains its structural signature after modification, whether buffer or excipient changes disturb conformation, and whether a small molecule exhibits meaningful optical activity. BOC Sciences offers specialized spectroscopy testing solutions centered on far-UV CD, near-UV CD, thermal denaturation, formulation-condition screening, and electronic circular dichroism (ECD) interpretation. Our service helps clients convert complex spectral responses into actionable structural conclusions, supporting confident candidate selection, analytical troubleshooting, and development-stage decision-making.
We provide far-UV CD measurements to evaluate protein and peptide secondary structure, helping clients assess α-helix, β-sheet, turn, and unordered structural contributions with clear spectral interpretation and structure characterization support.
Near-UV CD testing captures the asymmetric microenvironment of aromatic residues and disulfide regions, providing a sensitive fingerprint for tertiary packing, structural perturbation, and conformational comparability.
BOC Sciences performs temperature-ramp CD experiments to follow folding-to-unfolding transitions and generate stability indicators such as apparent Tm, transition breadth, reversibility, and aggregation-linked spectral distortion.
For chiral small molecules, natural products, atropisomers, and conformationally restricted APIs, we offer electronic circular dichroism testing to support stereochemical interpretation and chiroptical comparison.
BOC Sciences helps drug development teams interpret protein folding, peptide conformation, formulation effects, thermal stability, and chiral molecular behavior with rigorous CD spectroscopy testing.
We design far-UV CD experiments with appropriate pathlength, concentration, buffer transparency, scan speed, and baseline subtraction to maximize signal quality in the peptide-bond absorption region.
Our near-UV CD workflow focuses on sensitive tertiary-structure fingerprints, especially aromatic residue and disulfide environments that may change after mutation, conjugation, formulation adjustment, or thermal stress.
Controlled temperature ramping enables real-time tracking of folding transitions, apparent Tm, unfolding cooperativity, and post-cooling recovery for biologics, enzymes, peptides, and engineered protein constructs.
For chiral small molecules, we support ECD spectral acquisition, solvent-effect evaluation, enantiomeric comparison, and data interpretation as part of broader chiral analysis and separation projects.
CD findings can be integrated with UV-Vis testing, FTIR, fluorescence, Raman, and MS testing to support a broader analytical view of molecular structure and sample behavior.
Our analysts apply careful smoothing, baseline correction, unit conversion, replicate review, and secondary-structure modeling to convert spectra into concise, decision-ready analytical summaries.
BOC Sciences supports CD spectroscopy testing for a broad range of pharmaceutical and biotechnology samples. Because CD performance depends strongly on sample concentration, buffer absorbance, pathlength, and molecular behavior, our scientists review each project before testing and recommend practical acquisition conditions that protect both sample integrity and data interpretability.
Share your sample type, buffer composition, concentration range, and project objective. Our scientists will design a CD testing strategy that balances spectral sensitivity, sample consumption, and structural relevance.
We review the target molecule, sample concentration, available volume, buffer composition, expected structural question, and required comparison groups. This early assessment helps determine whether far-UV CD, near-UV CD, ECD, thermal ramping, or a combined study design is most appropriate.
Our team selects wavelength range, cuvette pathlength, scan speed, temperature, replicate number, and baseline strategy. When needed, we perform buffer exchange, dilution checks, or solubility analysis to reduce absorbance interference and aggregation risk.
Spectra are collected with appropriate blank controls and replicate review. We examine high-tension signals, baseline behavior, spectral smoothness, concentration normalization, and sample recovery to ensure that reported trends reflect molecular structure rather than measurement artifacts.
BOC Sciences provides processed spectra, comparison plots, secondary-structure estimates, thermal profiles, ECD interpretation, and a concise analytical discussion. When useful, results are connected with analytical technologies used in parallel studies.
Many biologics are formulated in buffers that absorb strongly in the far-UV region, making spectra noisy or truncated. BOC Sciences evaluates buffer transparency, pathlength, sample concentration, and dilution feasibility before acquisition. We can recommend buffer exchange, shortened pathlengths, or adjusted scan ranges so clients obtain interpretable CD data without forcing unrealistic sample conditions.
Early discovery proteins, rare peptides, and difficult-to-express constructs often have limited available material. Our workflow minimizes unnecessary sample use by designing fit-for-purpose pathlength and concentration conditions, performing preliminary absorbance checks, and selecting the most informative spectral region before committing material to expanded replicate or temperature-ramp studies.
Small changes caused by mutation, conjugation, oxidation, pH, ionic strength, or excipient exposure may not be obvious in a single spectrum. BOC Sciences applies matched controls, overlay comparison, difference spectra, replicate consistency review, and orthogonal analytical planning to help determine whether a spectral change is structurally meaningful or experimentally incidental.
Formulation teams often need to rank multiple buffer, pH, salt, surfactant, and excipient conditions by structural retention. We design CD-based screening matrices that connect conformational signatures with thermal behavior and visible aggregation trends, complementing stability studies and formulation decision-making.
Work with BOC Sciences to clarify folding state, thermal stability, chiral behavior, and formulation-driven conformational change through carefully designed CD spectroscopy testing and expert data interpretation.
We focus on the decision behind the spectrum: confirming folding, comparing variants, ranking formulations, evaluating stability, or interpreting chirality. Each study is structured around the client's development question rather than a generic scan request.
CD data quality is often limited by buffer absorbance, aggregation, scattering, or concentration uncertainty. BOC Sciences actively evaluates these variables and recommends practical adjustments before data collection.
CD testing can be combined with Fourier Transform Infrared Spectroscopy analysis, chromatography, mass spectrometry, fluorescence, and formulation evaluation for a more complete understanding of sample structure and behavior.
Clients receive processed spectra, overlays, comparison tables, deconvolution outputs, thermal transition plots, and expert interpretation written for project teams that need actionable conclusions, not only instrument-generated files.
Client Needs: A peptide discovery team needed to compare the helicity of six stapled peptide analogs designed for intracellular protein-protein interaction modulation. Their internal UV absorbance data could not confirm whether improved activity correlated with conformational stabilization.
Challenges: The peptides showed moderate aggregation above screening concentration, and the client required data in both aqueous buffer and a membrane-mimicking solvent system without consuming large quantities of material.
Solution: BOC Sciences first screened concentration windows and buffer transparency, then collected far-UV CD spectra for all six analogs under matched pathlength and temperature conditions. We processed triplicate spectra, corrected blanks, normalized mean residue ellipticity, and generated helicity estimates across two solvent environments to separate true conformational stabilization from aggregation-driven spectral distortion.
Outcome: Two analogs showed consistently higher helicity in both environments, giving the client a focused structural rationale for prioritizing them in the next in vitro activity and formulation evaluation.
Client Needs: A medicinal chemistry group requested ECD testing for a conformationally restricted chiral API intermediate containing an atropisomeric biaryl motif. They needed experimental chiroptical evidence to support stereochemical assignment during route refinement.
Challenges: The compound showed solvent-dependent spectral shifts and partial overlap between chromophore absorption bands, making simple visual comparison insufficient for confident stereochemical interpretation.
Solution: We acquired ECD and matched UV spectra in three solvent systems, optimized concentration to avoid saturation, and compared mirror-image spectral behavior between enriched fractions. BOC Sciences then aligned experimental ECD profiles with conformer-aware computational trends and reviewed the findings alongside orthogonal chromatographic data to assign the most consistent stereochemical model.
Outcome: The client received a coherent ECD interpretation package that clarified the dominant stereochemical assignment and identified the solvent system best suited for ongoing analytical comparison.
Client Needs: A biotechnology client needed to rank eight buffer and excipient combinations for an engineered enzyme that lost activity after storage at elevated temperature. Their main question was whether activity loss was associated with secondary-structure disruption.
Challenges: Several candidate buffers produced high absorbance below 205 nm, while surfactant-containing samples introduced light scattering that distorted the far-UV baseline.
Solution: BOC Sciences redesigned the matrix with shortened pathlength cuvettes, adjusted scan endpoints, and paired blank controls for each formulation. We collected initial spectra, temperature-ramp CD curves, and post-cooling recovery scans, then compared apparent Tm, spectral retention, and reversibility across eight conditions to identify the strongest stabilizing excipient profile.
Outcome: Three formulation conditions preserved the enzyme's secondary-structure signature after heating, enabling the client to narrow its pre-formulation screening plan to the most structurally protective candidates.
CD spectroscopy testing is well suited for conformational analysis of proteins, peptides, nucleic acids, chiral small molecules, and selected complex systems. For drug development teams, it is commonly used to determine whether a protein or peptide maintains its expected folding state, compare structural changes under different buffer, temperature, pH, excipient, or ligand conditions, and assess whether a sample shows aggregation, denaturation, or conformational drift. BOC Sciences can design far-UV, near-UV, or thermal CD testing strategies according to the sample type and research objective, helping clients obtain interpretable and comparable structural characterization data.
CD spectroscopy provides molecule-level conformational information, such as trends in protein secondary structures including α-helix, β-sheet, turn, and random coil content. Near-UV CD can also reflect changes in the microenvironment around aromatic residues or disulfide bonds, offering insight into tertiary structural alterations. For peptide and nucleic acid samples, CD spectra can help determine whether specific conformations are formed or whether structural transitions occur under different experimental conditions. It should be noted that CD does not provide atomic-resolution structures; rather, it is especially valuable for rapid comparison of conformational states, stability trends, and condition-screening outcomes.
In protein, peptide, and nucleic acid drug development, molecular structure status can directly influence formulation research, activity evaluation, and stability assessment. CD spectroscopy enables rapid observation of conformational changes with relatively low sample consumption, helping research teams screen suitable buffer systems, temperature conditions, excipient combinations, or storage environments. BOC Sciences can combine CD spectroscopy with thermal denaturation profiling, fluorescence analysis, particle size testing, and other characterization methods to build a multidimensional structural assessment strategy, providing clients with a more complete understanding of molecular stability and developability.
Protein stability is commonly evaluated by collecting CD spectra under different temperature, pH, ionic strength, excipient, or stress conditions, then comparing changes in characteristic peak intensity, peak position, and secondary structure trends. Thermal melting experiments can further monitor how a protein loses folding or undergoes conformational transition as temperature increases, helping compare stability differences among formulations, variants, or buffer conditions. During project execution, BOC Sciences carefully considers sample concentration, buffer background absorption, optical path length, scan range, and data processing methods to reduce experimental interference and improve the reliability and comparability of the results.
CD spectroscopy is sensitive to sample transparency, buffer composition, salt concentration, and background absorbance, so sample preparation should be planned carefully before testing. In general, buffer components with strong far-UV absorption should be avoided, and particles, precipitation, or turbidity should be minimized to reduce spectral interference. For protein and peptide samples, concentration, path length, and scan range should be selected appropriately to ensure suitable signal intensity for analysis. BOC Sciences can evaluate sample information before testing and help optimize buffer systems, dilution strategies, and testing parameters, making CD data more suitable for structural comparison and project decision-making.
BOC Sciences helped us understand why two recombinant protein variants behaved differently during formulation screening. Their CD overlays and interpretation were practical, technically sound, and immediately useful for our project discussion.
— Dr. Monroe, Principal Scientist, Protein Therapeutics
We had very limited peptide material and needed careful experimental design. The BOC Sciences team selected efficient CD conditions, minimized sample consumption, and delivered a report that clearly connected helicity with our analog design strategy.
— Ramsey, Director of Discovery Chemistry
The thermal CD study gave us a direct way to compare buffer systems for an unstable enzyme. Their review of reversibility and spectral recovery was especially valuable because it helped us avoid overinterpreting a single Tm value.
— Dr. Phelps, Senior Formulation Scientist
Our chiral intermediate had a complicated ECD profile, but BOC Sciences built a logical interpretation using solvent comparison and orthogonal data. The final summary was concise enough for management and detailed enough for our analytical chemists.
— Chapman, Analytical Project Manager
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
